That is the entire dataset
The medication is typically prescribed when diet and exercise alone, or in combination with other oral antidiabetic agents such as metformin, have not achieved adequate glycaemic control
Application Analysis The type 2 diabetes mellitus segment had a tremendous growth rate, with a revenue share of 62.3% owing to the well-established role of GLP-1 receptor agonists in improving glycemic control, promoting weight loss, and offering cardiovascular benefits in patients with type 2 diabetes
Key Takeaways Gastrointestinal events are the most common adverse effects: Nausea, diarrhea, and vomiting were reported in 4067% of participants at higher doses in published Phase 2 trial data Adverse events are dose-dependent: Higher retatrutide doses consistently produced higher rates of GI events across all published trials Most adverse events were mild to moderate: The Phase 2 trial reported the majority of events as Grade 1-2 in severity Discontinuation rates ranged from 610%: Published data shows dropout rates due to adverse events were comparable to other GLP-1 class compounds Retatrutide is not FDA-approved: All safety data comes from investigational clinical trials it remains a research compound What Clinical Trials Tell Us About Retatrutide Adverse Events Retatrutide (LY3437943) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously
Triple agonists Not yet available for medical use in Canada
